• Researcher Profile

    Christopher Sweeney, MBBS

     
    Christopher Sweeney, MBBS

    Top Doctor

     
    Associate Professor of Medicine, Harvard Medical School

    Center/Program

    Genitourinary Oncology

    Office phone: 617-632-4524
    Fax: 617-632-2165

    Preferred contact method: office phone

    View Physician Profile
     
     

    Interests

    Prostate cancer, Clinical trials, Testicular cancer, Bladder cancer, Kidney cancer, Hormone and chemotherapy

    Area of Research

    Preclinical drug development and drug evaluation, clinical trials in genitourinary malignancies (prostate, bladder, kidney, and testis cancer)

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    1230
    Boston, MA 02215

    Recent Awards

    • Chairman of the Hoosier Oncology Group, 2005-2007

    Research

    Preclinical drug development and drug evaluation, clinical trials in genitourinary malignancies (prostate, bladder, kidney, and testis cancer)

    Dr. Sweeney has focused his academic career on the management of genitourinary malignancies, including prostate, bladder, testis, and renal cell cancer. His research interest has been primarily focused on drug development. This has included (i) design and conduct of phase I trials of new agents or new combinations that assess the safety and distribution of the drug in the body as well as the anti-cancer activity of the therapy; (ii) assessment of genetic variants and blood markers to try and define signatures that identify patients who are destined to benefit from a therapy; (iii) design and conduct of phase 2 and 3 clinical trials with a focus on bladder and prostate cancer and (iv) drug discovery and evaluation in the laboratory to guide clinical trial design.

    Select Publications

    • Sweeney CJ, Williams SD, Finch DE, Bihrle, Foster RS, Collins M, Fox S, Roth BJ.  Phase II Study of Taxol and Ifosfamide in advanced refractory carcinoma of the urothelium.  Cancer 1999; 86: 514-19
    • Sweeney CJ, Hermans BP, Foster RS, Donohue JP, Einhorn LH Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma predominant testis cancer. J  Clin Oncology; 2000; 15: 358-362
    • Hermans BP, Sweeney CJ, Foster RS, Donohue JP, Einhorn LH Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urology: 2000: 163; 1721-1724
    • Sweeney CJ, Sandler, AB, Zhu J, Schiller, J, Belani, CP, Langer, C, Krook J, Harrington, D, Johnson, DH.  A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) – Outcome of performance status 2 patients in the Eastern Co-operative Group trial E1594. Cancer 2001: 92; 2639-47
    • Sweeney, C, Monaco, F, Hanna, N, Wasielewski, M, Picus, J, Ansari, R, Dugan D, Einhorn LH. A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone Refractory Prostate Cancer. Ann Oncol 2002: 13; 435-40
    • Curry, E.A,III, Murry, D.J., Yoder, C., Fife, K., Armstrong, V., Nakshatri, H., O’Connell, M., Sweeney C.J., Phase I Dose Escalation Trial of Feverfew with Standardized Doses of Parthenolide in Patients with Cancer. Invest New Drugs. 2004, 22(3):299-305
    • Kaufman H, Wang W, Manola J, DiPaola R, Ko YK, Sweeney C, Whiteside T, Schlom J, Wilding G, Weiner L. Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897):  A Trial of the Eastern Cooperative Oncology Group J Clin Oncol. 2004 Jun 1;22(11):2122-32
    • Li J, Juliar B, Ansari R, Fox E, Fisch M, Einhorn L, Sweeney C. Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium: A Phase II Study of Hoosier Oncology Group.  Journal of Clinical Oncology. 2005 Feb 20;23(6):1185-91
    • Sweeney C, Liu G, Horvath D,  Staab MJ, Fife K, Armstrong A, Treston A, Sidor C, Wilding G. Phase 2, multicenter, randomized, double blind, safety, pharmacokinetic, pharmacodynamic and efficacy study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer. Clin Cancer Res. 2005 Sep 15;11(18):6625-33.
    • Sweeney, C.,  Roth, B., Kabbinavar, F, Vaughn, D., Arning, M., Curiel, R., Oasaju, C., Wang, Y., Nicol, S., Kaufman D., Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. Journal of Clinical Oncology Jul 20 2006: 3451–3457
    • Mita A, Sweeney C, Baker S, Goetz A, Felton S, Hammond L, Patnaik A, Tolcher A, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz J, Simms L, Chaudhary A, Johnson R, Rowinsky E, Takimoto C. A Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients with Normal and Impaired Renal Function. Journal of Clinical Oncology Feb 1 2006: 552–562
    • Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006;12:6094-9.
    • Agus D, Sweeney C, Morris M, Mendelson D, McNeel D, Ahmann F, Wang J, Derynck M, Lyons, B, Kattan M, Scher H;  Efficacy And Safety Of Single Agent Pertuzumab (rhuMAb 2C4), A HER Dimerization Inhibitor, In Hormone Refractory Prostate Cancer After Failure Of Taxane-Based Therapy. J. Clin Oncology 2006; 2007, 25: 675-681.
    • Schneider, B, Yoder, C, Fife, K, Dropcho, S, Rosenberg, L, Kelich, S, Gordon, M, Seitz, D, Fukunaga, A, Murry, D A, Sweeney, C.J.  Phase I Dose Escalation Trial of Weekly Paclitaxel and Interferon-alfa2b with Pharmacokinetic and Pharmacodynamic Endpoints Cancer Chemotherapy and Pharmacology 2007 Feb;59(2):261-8
    • Chiorean E.G., Porter J.M., Foster, A.E, Al Omari, A.,  Yoder CA, Fife, KL, Strother, M, Murry, DJ, Yu, M, Jones, D.R., Sweeney, CJ., A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane Naive Malignancies.  Clin Cancer Res. 2008 Feb 15;14(4):1131-7.
    • Hahn N, Zon RT., Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. A Phase II Study of Pemetrexed as Second-Line Chemotherapy for the Treatment of Metastatic Castrate Resistant Prostate Cancer (CRPC); Hoosier Oncology Group GU03-67, Ann Oncol. 2009 Dec;20(12):1971-6.
    • Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010 Jul;66(2):345-56.
    • Gordon MS, Sweeney CJ, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L. Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 2010 Jan 15;16(2):699-710.
    • Rosen P., Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM Shubhakar P., Zhu M, Oliner KS, Anderson A, Yee L.K. A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2010 May 1;16(9):2677-87.
    • Chiorean EG, Malireddy S, Younger AE, Jones DR, Waddell MJ, Sloop MI, Yu M, Hall SD, Schneider B, Sweeney CJ. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Aug;66(3):441-8.
    • Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, Lorusso P. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Dec;88(6):818-23.
    • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon, PM, Active surveillance compared with initial treatment for men with low-risk prostate cancer:  a decision analysis. JAMA. 2010 Dec;304(21):2373-80. 
    • Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20;29(12):1525-30.
    • Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, Dewolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded Prostate Cancer Index Composite for Clinical Practice: Development and Validation of a Practical Health Related Quality of Life Instrument for Use in the Routine clinical Care of Patients With Prostate Cancer.  J  Urol. 2011 Sep;186(3):865-72.
    • Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr;22(4):801-7. 
    • Harrison, M., Sweeney, C.J. Hahn, N., A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal® Dispersion (NCD) in Patients with Taxane-Refractory, Metastatic Castrate-Resistant Prostate Cancer (CRPC). Invest New Drugs. 2011 Dec;29(6):1465-74
    • Patel YR, Carr KA, Magjuka D, Mohammadi Y, Dropcho EF, Reed AD, Moore ML, Waddell MJ, Shedd-Steele R, Sweeney CJ, Hahn NM. Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations. Cancer. 2012 Feb 15;118(4):1075-82
    • Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma., Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):383-9
    • Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 4;4(128):128ra39.
    • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9.
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now